Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01012609 : External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
PhasePhase 2
AgesMin: 3 Years Max: 21 Years
Eligibility
Inclusion Criteria:

- Patients must have either (1) histologic proof of a high-grade astrocytoma reviewed
by a POETIC institutional pathologist or (2) a radiological diagnosis via MRI scan of
a typical diffuse pontine tumor made by a POETIC institutional neuroradiologist.
Patients with a radiological diagnosis via MRI scan of a typical diffuse pontine
tumor will be enrolled on the diffuse pontine tumor arm of the study regardless of
histology in cases that are biopsied. Note: For collaborating non-POETIC
institutions, the reviews may be done by an institutional
pathologist/neuroradiologist.

- Patients must begin study prescribed therapy within 42 days of neurosurgical
resection or biopsy of the tumor (high-grade astrocytoma patients) or radiological
diagnosis (diffuse pontine tumor patients).

- Age ? 3-years and < 22-years-old.

- Brain MRI (and any other studies done according to clinical indications) must not
show any definitive evidence of leptomeningeal or extra-neural metastases.

- ANC ? 1000/?L and platelet count ? 100,000/?L

- Patients must have adequate organ function as defined by:

- Hepatic: total bilirubin < 1.5 mg/dl, AST ? 2.5 x the upper limit of normal.

- Renal: serum creatinine ? 1.5 x the upper limit of normal for age, or calculated
creatinine clearance or nuclear GFR ? 70 ml/min/1.73 m2.

- The patient, or for minors, a parent or legal guardian, must give informed written
consent indicating they are aware of the investigational nature of this study.

Exclusion Criteria:

- Evidence of leptomeningeal or extra-neural metastatic disease.

- Prior radiation therapy or chemotherapy

- Pregnancy, mothers unwilling to refrain from breast-feeding, and sexually mature
patients unwilling to practice an effective form of birth control.

- Other significant concomitant medical illnesses that would compromise the patient's
ability to receive all prescribed study therapy.

- Prior therapy which specifically and directly targets the EGFR pathway.

- Prior severe infusion reaction to a monoclonal antibody.

- Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension,
unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled
congestive heart failure, and cardiomyopathy with decreased ejection fraction.

- Patients with known Gilbert's Syndrome.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01012609      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740